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OBJECTIVE: To analyze the prevalence of myositis-specific and myositis-associated autoantibodies and their
clinical correlations in a large series of patients with dermatomyositis/polymyositis.
METHOD: This cross-sectional study enrolled 127 dermatomyositis cases and 95 polymyositis cases. The disease-
related autoantibody profiles were determined using a commercially available blood testing kit.
RESULTS: The prevalence of myositis-specific autoantibodies in all 222 patients was 34.4%, whereas myositis-
associated autoantibodies were found in 41.4% of the patients. The most frequently found autoantibody was
anti-Ro-52 (36.9%), followed by anti-Jo-1 (18.9%), anti-Mi-2 (8.1%), anti-Ku (4.1%), anti-SRP (3.2%), anti-PL-7
(3.2%), anti-PL-12 (2.7%), anti-PM/Scl75 (2.7%), and anti-PM/Scl100 (2.7%). The distributions of these
autoantibodies were comparable between polymyositis and dermatomyositis, except for a higher prevalence
of anti-Jo-1 in polymyositis. Anti-Mi-2 was more prevalent in dermatomyositis. Notably, in the multivariate
analysis, anti-Mi-2 and anti-Ro-52 were associated with photosensitivity and pulmonary disorders, respectively,
in dermatomyositis. Anti-Jo-1 was significantly correlated with pulmonary disorders in polymyositis. Moreover,
anti-Ro-52 was associated with anti-Jo-1 in both diseases. No significant correlation was observed between the
remaining autoantibodies and the clinical and/or laboratory findings.
CONCLUSIONS: Our data are consistent with those from other published studies involving other populations,
although certain findings warrant consideration. Anti-Ro-52 and anti-Jo-1 were strongly associated with one
another. Anti-Ro-52 was correlated with pulmonary disorders in dermatomyositis, whereas anti-Jo-1 was
correlated with pulmonary alterations in polymyositis.
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& INTRODUCTION
Idiopathic inflammatory myopathies (IIMs) constitute a
heterogeneous group of chronic systemic autoimmune
diseases with high morbidity and disability rates (1).
Based on their clinical and histopathological features, IIMs
can be classified as polymyositis (PM), dermatomyositis
(DM), juvenile dermatomyositis, inclusion body myositis,
malignancy-associated myositis, and other collagen disease-
associated types of myositis.
The etiologies of PM and DM remain unknown, but they
are believed to be multifactorial and might include genetic,
immunological, and environmental causes. Moreover, there
is strong evidence that cellular and humoral autoimmune
mechanisms play important roles in these myopathies (2,3).
Previous studies have reported that more than 50% of IIM
patients have high autoantibody titers, but recent studies
using high-sensitivity techniques have shown that the
frequency of autoantibody positivity could reach 80%
(4,5). The description of a broad spectrum of myositis-
specific autoantibodies (MSAs) and myositis-associated
autoantibodies (MAAs) (5-12) has allowed for better clinical
categorization of IIMs at diagnosis. Moreover, the char-
acterization of different MSAs and MAAs has provided
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evidence of their putative clinical prognostic value and
associations (5).
However, the majority of past studies have generally
analyzed MSA and/or MAA profiles in patient groups with
autoimmune IIM, without discriminating between DM and
PM in subgroups (13), in small groups of DM or PM patients
(6,11,14), and in DM/PM overlap syndrome, malignancy-
associated myositis, inclusion body myositis and/or other
collagen disease-associated types of myositis (6,11-13).
Moreover, no similar studies analyzing MSAs and MAAs
have been performed in a Brazilian population with DM
and PM.
Herein, we compared MSA and MAA autoantibody
reactivity patterns and their possible clinical associations
in a large series of Brazilian patients with autoimmune IIM,
including PM and DM.
& MATERIALS AND METHODS
The present cross-sectional study involved 222 patients
with DM/PM who met at least three (for PM) or four (for
DM) of the criteria defined by Bohan and Peter (15). All
patients were treated for inflammatory myopathies in the
outpatient clinic of a tertiary hospital center. The patients
(aged $18 years) were selected based on the availability of
serum samples that had been obtained at the time of
diagnosis (from 2000-2012) and stored at -20 C˚. The patients
with systemic autoimmune comorbidities or malignancies
were excluded.
Patient demographic features and clinical manifestations
at disease onset were obtained through a systematic review
of medical records. These features included bodily symp-
toms, cutaneous involvement (i.e., heliotrope, Gottron’s
sign, ‘‘V’’ of the neck, Shawl’s sign, photosensitivity,
Raynaud’s phenomenon, ulcers, or calcinosis), heart invol-
vement (i.e., myocarditis or heart failure, as revealed by
myocardial scintigraphy and echocardiogram exam), gas-
trointestinal tract involvement (upper dysphagia), articular
involvement (arthralgia or arthritis), pulmonary disorders
(incipient pneumopathy, ground-glass lesions and/or basal
pulmonary fibrosis, as revealed by computed tomography
[CT]), and limb muscle strength graded according to the
Medical Research Council classification: grade 0, absence of
muscle contraction; grade I, slight signs of contractility;
grade II, movements of normal amplitude but not against
the force of gravity; grade III, normal range of motion
against gravity; grade IV, full mobility against gravity and
against a degree of resistance; and grade V, complete
mobility against strong resistance and against the force of
gravity (16).
Laboratory evaluations were performed at disease onset
using automated kinetic methods. The evaluations included
determining the serum levels of creatine kinase (normal
range, 24-173 IU/L), lactate dehydrogenase (20-350 IU/L),
alanine aminotransferase (10-36 IU/L), aspartate amino-
transferase (10-36 IU/L), and aldolase (1.0-7.5 IU/L). The
erythrocyte sedimentation rate ([ESR] , 20 mm/1st hour)
and C-reactive protein ([CRP] ,5 mg/L) levels were
obtained using the Westergren and immunoturbidimetric
methods, respectively, at the time of diagnosis.
The following autoantibodies were investigated in this
study: anti-Jo-1 (histidyl-), anti-PL-7 (threonyl-), anti-PL-12
(alanyl-), anti-EJ (glycol-), anti-OJ (isoleucyl-tRNA synthe-
tase), anti-SRP (signal recognition particle), anti-Mi-2 — all
included in the group of MSA autoantibody profiles; and
anti-PM-Scl 75, anti-PM-Scl 100, anti-Ku, anti-Mi-2, and
anti-SS-A/Ro-52 kDa — all belonging to the MAA autoanti-
body profile. For assessment, a commercially available line
blot test kit (Myositis Profile Euroline Blot test kit,
Euroimmun, Lu¨beck, Germany) was used according to the
manufacturer’s protocol. The results were arbitrarily
defined as negative (0/+++), weakly (+/+++), moderately
(++/+++), or strongly (+++/+++) reactive by two indepen-
dent researchers (MGPC and SKS) who had no knowledge
of the diagnostic data from each analyzed case. In the
present study, only the moderate or strong reactivity results
were considered.
Statistical analysis. The Kolmogorov-Smirnov test was
used to evaluate the distribution of each parameter. The
demographic and clinical features are expressed as the
means and standard deviations (SD) for the continuous
variables or as frequencies and percentages for the
categorical variables. The medians (25th-75th percentiles)
were calculated for the continuous variables that were not
normally distributed. Comparisons between the patients
with and without specific autoantibodies were performed
using Student’s t-test or the Mann-Whitney u-test for
continuous variables, and p,0.05 was considered signifi-
cant. Moreover, for each disease (DM or PM), all statistically
significant univariate parameters that were considered for
adjustment were selected and analyzed by stepwise multi-
ple logistic regression (multivariate analysis). Pearson’s chi-
squared test or Fisher’s exact test was used to evaluate the
categorical variables. Age at disease onset and gender were
adjusted, and the measurements are expressed as odds
ratios (ORs) with 95% confidence intervals (CIs). The
STATA computer program, version 7 (STATA, College
Station, TX USA), was used for the statistical analysis.
& RESULTS
Demographic and clinical features of patients
The median ages at disease onset (interquartile ranges)
were 43 years (33-57) and 41 years (31-53) for the PM and
DM patients, respectively, with a predominance of female
gender and Caucasian race in both groups (Table 1).
Bodily symptoms occurred in half of the patients in both
groups. Regarding extra-muscular manifestations, articular
involvement affected approximately 40% of the PM and DM
patients, followed by dysphagia and Raynaud’s phenom-
enon. Approximately one-fourth of the PM and DM patients
were bedridden, and 10% of had dysphonia. No heart
involvement was found in either group. As expected,
cutaneous involvement was exclusively or more frequently
observed in the DM patients and included heliotrope,
Gottron’s sign, photosensitivity, and other symptoms (e.g.,
ulcers, calcinosis, ‘‘V’’ of the neck, and Shawl’s sign). At the
time of diagnosis, muscle weakness was categorized as
grade IV (upper and lower limbs) in the majority of PM and
DM patients.
Pulmonary disorders, demonstrated by CT, were observed
in one-third of the patients in both groups.
The median serum levels of muscle-related enzymes were
increased in all PM patients and in approximately 90% of
the DM patients (Table 1). Similarly, the median values for
ESR and CRP were increased in both groups.
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The prevalence of reactivity to any autoantibody (MSA
and/or MAA) was 54.1% in all patients included in this
study. Patients from the PM and DM subgroups had similar
prevalences of reactivity, 58.9% vs. 50.4%, respectively
(p= 0.223). A higher prevalence of MSA was observed in
the PM patients (45.3% vs. 13.5%, p= 0.036) because of
higher positivity for anti-Jo-1 in this subgroup (31.6% vs.
9.5%, p,0.001). Conversely, anti-Mi-2 was more frequently
found in the DM patients (11.8% vs. 3.2%, p=0.019).
Reactivity to the remaining MSA-related autoantibodies
was low (,5%) and was comparable between the DM and
PM patients. Anti-OJ binding was not found in any of the
patients studied. Concomitant positivity for any of the
autoantibodies included in the MSA and MAA sets was
more frequently observed in the PM patients than in the DM
patients (31.6% vs. 19.7%, p= 0.042). MAA positivity was
similar in both groups (p= 0.317). The percentages of
patients with reactivity to these autoantibodies among the
PM and DM patients are shown in Table 2.
No differences in age at disease onset, gender, or clinical or
laboratory findings were observed among the DM and PM
patients with distinct MSA and/or MAA profiles. However,
the univariate analysis showed that anti-Mi-2-positive DM
patients were significantly more likely to exhibit photosensi-
tivity and Shawl’s sign (Table 3). Moreover, in the multi-
variate analysis, only the DM patients who were anti-Mi-2-
positive were significantly more likely to be photosensitive.
Furthermore, anti-Ro-52-positive DM patients were signifi-
cantly more likely to exhibit pulmonary disorders and anti-
Jo-1 positivity, as revealed by the univariate and multivariate
analyses. Anti-Jo-1 reactivity was associated only with anti-
Ro-52 positivity and not to a particular clinical manifestation
in these patients (Table 3). Similarly, there was no significant
association between the other MSAs and MAAs and any
clinical or laboratory profiles for DM.
Similar to the MAA findings in DM patients, anti-Ro-52-
positive PM patients were significantly more likely to exhibit
pulmonary disorders and positivity to anti-Jo-1 than those
patients who were anti-Ro-52-negative, as demonstrated by
the univariate analysis. In the multivariate analysis, only
pulmonary disorders were independently associated with
anti-Ro-52 positivity in the PM patients. Contrasted with the
findings in DM patients, anti-Jo-1-positive PM patients were
Table 1 - Demographic, clinical and laboratory features of the patients with DM and PM at the time of diagnosis.
All (n = 222) PM (n=95) DM (n=127) p-value
Age at disease onset (years) 41 (31-54) 43 (33-57) 41 (31-53)
Female gender 171 (77.0) 67 (70.5) 104 (81.9) 0.054
Caucasian 191 (86.0) 79 (83.2) 115 (90.6) 0.185
Clinical manifestations
Bodily symptoms 109 (49.1) 47 (49.5) 62 (48.8) 0.928
Articular involvement 89 (40.1) 45 (47.4) 44 (34.7) 0.056
Dysphagia 77 (33.8) 27 (28.4) 48 (37.8) 0.144
Dysphonia 26 (11.7) 8 (8.4) 18 (14.2)
Heart involvement 0 0 0 1.000
Cutaneous involvement
Heliotrope 107 (48.2) 0 107 (84.3) ,0.001
Gottron’s sign 117 (52.7) 0 117 (92.1) ,0.001
Photosensitive 76 (34.2) 14 (14.7) 62 (48.8) ,0.001
Raynaud’s phenomenon 69 (31.1) 24 (25.3) 45 (35.4) ,0.001
Others* 61 (27.5) 1 (1.1) 60 (47.2) ,0.001
Muscle strength
Upper limbs
Grade I 3 (1.4) 1 (1.1) 2 (1.6) 0.865
Grade II 3 (1.4) 2 (2.1) 1 (0.8)
Grade III 40 (18.0) 18 (18.9) 22 (17.3)
Grade IV 159 (71.6) 68 (71.6) 91 (71.6)
Grade V 17 (7.6) 6 (6.3) 11 (8.7)
Lower limbs
Grade I 2 (0.9) 1 (1.1) 1 (0.8) 0.274
Grade II 6 (2.7) 3 (3.2) 3 (2.4)
Grade III 46 (20.7) 22 (23.2) 24 (18.9)
Grade IV 162 (73.0) 69 (72.6) 93 (73.2)
Grade V 6 (2.7) 0 6 (4.7)
Pulmonary involvement
CT** 70 (31.5) 30 (31.5) 40 (31.5) 1.000
Muscle enzyme alterations 208 (93.7) 95 (100) 113 (89.0)
Creatine kinase (IU/L) 2118 (597-5000) 2989 (1210-5000) 1007 (228-5178) 0.007
Aldolase (IU/L) 23 (9-56) 27 (15-75) 13 (7-45) 0.002
Lactic dehydrogenase (IU/L) 819 (560-1588) 815 (681-1537) 845 (556-1594) 0.471
AST (IU/L) 95 (45-234) 113 (53-228) 88 (43-238) 0.468
ALT (IU/L) 83 (39-178) 104 (50-223) 75 (33-149) 0.047
ESR (mm/1st h) 21 (11-39) 20 (9-34) 25 (13-40) 0.117
CRP (mg/L) 6.2 (3.0-13.6) 6.8 (2.4-15.9) 6.1 (3.4-10.4) 0.792
Values are expressed as n (%) or as medians (interquartile range). *Ulcers, photosensitive, calcinosis, ‘‘V’’ of the neck, Shawl’s sign **incipient
pneumopathy, ground-glass lesions and/or basal pulmonary fibrosis.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; DM, dermatomyositis, ESR, erythrocyte sedimentation rate;
PM, polymyositis.
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significantly more likely to exhibit pulmonary disorders and
articular manifestations than the anti-Jo-1-negative patients.
However, the multivariate analysis revealed that anti-Jo-1
reactivity was associated only with pulmonary disorders and
anti-Ro-52 positivity with articular manifestations. Other
MSAs and/or MAAs were not associated with any clinical or
laboratory profiles for PM (Table 3).
& DISCUSSION
Previous studies have shown that more than 50% of IIM
patients have high titers of autoantibodies. However, new
and improved detection methodologies established in
conjunction with the descriptions of new target antigens in
IIMs have contributed to the finding that the frequency of
circulating autoantibodies against nuclear or cytoplasmic
constituents with ubiquitous tissue distribution could be up
to 80% in patients with DM/PM (2). In the present study,
we observed positivity for MSA and/or MAA in half of the
patients with DM/PM.
The target antigens in the IIMs are intracellular proteins
that are involved in key processes in cells, such as gene
transcription, protein synthesis and translocation. These
antigens include the aminoacyl-tRNA synthetase family of
enzymes, nuclear helicase Mi-2/histone deacetylase com-
plex, and SRP (3,17-31).
In the present study,MSA andMSA +MAAwere observed
more frequently in the PM patients than in the DM patients,
whereas MAAs had similar distributions in both groups.
Among the MSA group of antibodies, anti-Jo-1 (anti-histidyl-
tRNA synthetase) is themost prevalent (3,17,18) and themost
common anti-aminoacyl-tRNA synthetase autoantibody
described to date, characterizing anti-synthetase syndrome.
However, this positivity is not an exclusive serological
finding, as other autoantibodies can be present in this
syndrome, including anti-EJ (glycyl-), anti-PL-7 (threonyl-),
anti-PL-12 (alanyl-), anti-OJ (isoleucyl-), anti-KS (asparagi-
nyl-), anti-Ha (tyrosinyl-), anti-Zo (phenylalanyl-), and anti-
YRS (tyrosyl-) (18-26). The clinical presentation of patients
with these autoantibodies is relatively homogeneous, with
one or more of the following signs: myositis, interstitial lung
disease, and joint involvement. The presence of fever,
Raynaud’s phenomenon and "mechanical hands" has also
been observed (17-26). In agreement with the data from the
literature, we found a predominance of anti-Jo-1 in our series
of IIM patients, compared to other anti-aminoacyl-tRNA
synthetase antibodies. In our series, anti-Jo-1 was more
significantly present in the PM patients than in the DM
patients. When analyzed by disease, anti-Jo-1 was signifi-
cantly associated with anti-Ro-52 reactivity, but it was not
correlated with pulmonary disorders or articular manifesta-
tions in DM patients. In contrast, in the group of PM patients,
this autoantibody was correlated with pulmonary disorders
and anti-Ro-52 reactivity.
Concerning the other anti-aminoacyl-tRNA synthetase
antibodies, we found low prevalences in the present study.
Moreover, we did not observe patients with positivity to
anti-OJ.
Another subgroup of patients with IIMs is characterized
by the presence of antibodies directed against SRP. This
antibody has been detected in the serum of 4-6% of patients
with IIMs (27-29), whereas in the present study, we found
this positivity in 3.2% of the patients. Myopathies associated
with anti-SRP antibodies are characterized by aggressive
necrotizing myositis, which is evidenced by rapidly
progressive proximal muscle weakness and marked
increases in the creatine kinase level. Moreover, anti-SRP-
positive patients are less responsive to conventional drug
Table 2 - Frequency of myositis-specific and myositis-
associated autoantibodies in patients with DM and PM.
All (n = 222) PM (n=95) DM (n=127) p-value
MSA positivity 83 (34.4) 43 (45.3) 40 (31.5) 0.036
Anti-Jo-1 42 (18.9) 30 (31.6) 12 (9.5) ,0.001
Anti-Mi-2 18 (8.1) 3 (3.2) 15 (11.8) 0.019
Anti-SRP 7 (3.2) 4 (4.2) 3 (2.4) 0.436
Anti-PL-7 6 (2.7) 3 (3.2) 3 (2.4) 0.997
Anti-PL-12 7 (3.2) 3 (3.2) 4 (3.1) 0.718
Anti-EJ 6 (2.7) 2 (2.1) 4 (3.1) 0.635
Anti-OJ 0 0 0 1.000
MAA positivity 92 (41.4) 43 (45.3) 49 (38.6) 0.317
Anti-SSA/Ro-52 82 (36.9) 37 (38.9) 45 (35.4) 0.591
Anti-Ku 9 (4.1) 7 (7.4) 2 (1.6) 0.350
Anti-PM/Scl75 6 (2.7) 1 (1.1) 5 (3.9) 0.297
Anti-PM/Scl100 5 (2.3) 1 (1.1) 4 (3.1) 0.190
MSA+MAA
positivity
55 (24.8) 30 (31.6) 25 (19.7) 0.042
MSA and/or MAA 120 (54.1) 56 (58.9) 64 (50.4) 0.223
Values are expressed as n (%). P-value, comparison between the PM and
DM groups. DM, dermatomyositis; PM, polymyositis.
Table 3 - Independent associations of autoantibodies with specific sets of clinical, imaging, and laboratory features by
stepwise multiple logistic regression in patients with DM and PM.
Diseases MSA/MAA Parameters Univariate Multivariate
OR 95% CI p-value OR 95% CI
Dermatomyositis Anti-Mi-2 Photosensitive 8.6 1.9-40.1 0.002 7.3 1.5-35.4
Shawl’s sign 5.2 1.1-24.9 0.020 2.5 0.5-12.1
Anti-Ro-52 Pulmonary disorders 3.1 1.4-7.0 0.006 2.8 1.2-6.6
Anti-Jo-1 16.5 3.2-84.3 ,0.001 14.9 2.8-79.4
Anti-Jo-1 Anti-Ro-52 15.9 3.1-82.9 ,0.001 15.9 3.1-82.9
Polymyositis Anti-Ro-52 Pulmonary disorders 4.7 1.8-12.2 0.001 2.8 1.0-7.9
Anti-Jo-1 7.0 2.7-18.6 ,0.001 5.0 1.8-14.0
Anti-Jo-1 Articular manifestations 3.1 1.3-7.8 0.010 2.2 0.7-6.3
Pulmonary disorders 6.8 2.5-18.2 ,0.001 3.9 1.3-11.6
Anti-Ro-52 7.0 2.7-18.6 ,0.001 5.1 1.8-14.5
OR, odds ratio; CI, confidence interval; MSA, myositis-specific autoantibodies; MAA, myositis-associated autoantibodies.
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treatments (27-29). In our series, we found anti-SRP
antibodies in seven patients (four PM and three DM
patients), and in contrast to the literature, there were no
correlations with signs of myositis severity or heart disease.
The anti-Mi-2 autoantibody is strongly associated with
skin manifestations in juvenile and adult DM, with a low
risk of interstitial pulmonary involvement and a good
disease prognosis (31). Our findings demonstrated a
correlation of anti-Mi-2 with different types of DM skin
lesions, but in the multivariate analysis, this autoantibody
was associated only with photosensitivity.
The main components of the Ro/SS-A system are two
distinct major proteins with molecular weights of 52 kDa
(Ro-52) and 60 kDa (Ro-60) (32). Reactivity to the Ro-SS-A
protein has been correlated with the clinical features of
Sjo¨gren’s syndrome and systemic lupus erythematosus (33).
However, the presence of anti-Ro in IIMs has also been
described (34-36), and the association of anti-Ro-52 with
anti-Jo-1 has been described in IIM patients in 10% of cases
(34-36). Particularly in patients with anti-synthetase syn-
drome, the presence of anti-SSA/Ro-52 antibodies causes
more severe interstitial lung disease (37). Other authors
have found that the presence of anti-Ro-52 is associated with
a particular phenotype of anti-synthetase syndrome, result-
ing in more severe myositis and joint impairment.
Moreover, the coexistence of anti-Ro-52 appears to be
associated with an increased risk of cancer (38). In the
present study, anti-Ro-52 was significantly associated with
anti-Jo-1, independent of the type of disease. However, in
DM patients, anti-Ro-52 was associated with pulmonary
disorders, independent of anti-Jo-1 reactivity.
Regarding MAAs, anti-PM-Scl has been found in 8-10% of
patients with myositis-scleroderma overlap, whereas anti-
Ku has been observed in 20-30% of these patients (3,9,39,40).
The prevalence described herein was lower and could be
explained by the exclusion of systemic autoimmune disease
comorbidities, such as systemic sclerosis. Furthermore,
these autoantibodies were not correlated with any clinical
or laboratory parameters of DM or PM.
Our study was limited by being a retrospective study,
with the typical problems specific to this type of cohort.
Second, in the present study we also included patients with
probable diagnoses of PM (i.e., meeting three of the four
Bohan and Peter’s criteria) (15). In these cases, it was not
possible to distinguish inclusion body myositis from other
types of myositis or from certain dystrophies. Third, the
blood samples had been stored for approximately 10 years
and, therefore, might not have functioned properly in the
antibody assays. Additionally, we did not include a healthy
control group with which to compare antibody reactivity
among the groups.
In conclusion, our data are consistent with those from
other published studies involving other populations,
although certain particularities do warrant consideration:
a) we observed high frequencies of anti-Jo-1 and anti-Ro-52,
followed by anti-Mi-2, in the subjects of the present study;
b) anti-Ro-52 and anti-Jo-1 were strongly associated with
one another; c) anti-Ro-52 was correlated with pulmonary
disorders in dermatomyositis, whereas anti-Jo-1 was corre-
lated with pulmonary alterations in polymyositis; and d)
these autoantibodies should be analyzed routinely in
practice, in contrast to the other MSAs and MAAs that
were present in low frequencies and that were not
associated with the clinical or laboratory parameters of
PM and DM.
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